Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elekta ABEKTAY -2.36%74 EBITDA Margin % is -4.60% as of Apr. 2026. GuruFocus rates EKTAY with a GF Score™ of 74/100 and a GF Value™ of $6.51 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Elekta AB ranks better than 51.04% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Elekta AB's EBITDA for the
three
months ended in Apr. 2026 was $-24 Mil. Elekta AB's Revenue for the
three
months ended in Apr. 2026 was $514 Mil. Therefore, Elekta AB's EBITDA margin for the quarter that ended in Apr. 2026 was -4.60%.
Elekta AB (OTCPK:EKTAY) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Elekta AB EBITDA Margin % Related Terms
Elekta AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Elekta AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EKTAY vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Elekta AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elekta AB EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Elekta AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Elekta AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elekta AB (EKTAY) has a EBITDA Margin % of -4.60% as of Apr. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Elekta AB and its competitors. Over the past decade, Elekta AB's EBITDA Margin % has ranged from 8.09 to 22.28. According to the industry distribution chart, Elekta AB ranks #399 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 49%.
Is Elekta AB's EBITDA Margin % too high?
Elekta AB's current EBITDA Margin % is -4.60%. Over the past 10 years, this metric has ranged from a low of 8.09 to a high of 22.28. Based on the distribution chart, Elekta AB ranks #399 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Elekta AB has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Elekta AB's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Elekta AB ranks #399 out of 815 companies for EBITDA Margin %. This puts Elekta AB in the upper half of its industry. The industry median EBITDA Margin % is 7.47. Historically, Elekta AB's own EBITDA Margin % has ranged from 8.09 to 22.28 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Elekta AB and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elekta AB's current EBITDA Margin % is -4.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elekta AB stock overvalued right now?
Based on GuruFocus' analysis, Elekta AB (EKTAY) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.51, compared to a current price of $4.63 — trading 28.9% below its estimated fair value. The current EBITDA Margin % is -4.60%. Elekta AB's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Elekta AB (EKTAY), the current EBITDA Margin % is -4.60% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elekta AB (EKTAY) Overvalued in 2026?
Based on GuruFocus' analysis, Elekta AB stock appears to be undervalued.
The current stock price of $4.63 is trading 28.9% below its estimated GF Value™ of $6.51.
GuruFocus considers Elekta AB to be Modestly Undervalued.
Key valuation signals for EKTAY:
EBITDA Margin %: -4.60%
GF Value™: $6.51 vs. price of $4.63 (28.9% below fair value)
No single metric tells the full story. See the EKTAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company has an installed base of more than 7,300 linear accelerators, Gamma Knife and Unity platforms, as well as brachytherapy installations. The company's sales are evenly distributed across geographies, with North and South America accounting for 29%; Europe, the Middle East, and Africa accounting for 37%; and the Asia-Pacific contributing the remainder.
74GF Score
Get the complete analysis for EKTAY
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EKTAY has been successfully added to your 
